Michael A. Morse

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.7K citations · Full text

Checkmate 142, Medicine, Colorectal Cancer +8

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Christine H. Chung, Beloo Mirakhur, Emily Chan et al. · New England Journal of Medicine · 2008 · 1.5K citations · Full text

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Checkmate 032, Pharmacology +5

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

Michael A. Morse, Jennifer Garst, Takuya Osada et al. · Journal of Translational Medicine · 2005 · 1.1K citations · Full text

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma, Margaret K. Callahan, Petri Bono et al. · The Lancet Oncology · 2016 · 676 citations · Full text

Urology, Genitourinary Cancer, Medicine +7